BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25426666)

  • 21. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.
    Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E
    Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
    Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
    Bentur OS; Gurion R; Gafter-Gvili A; Gatt M; Shvidel L; Horowitz NA; Ram R; Herishanu Y; Sarid N; Paltiel O; Ganzel C; Kreiniz N; Dally N; Gutwein O; Raanani P; Avivi I; Perry C
    Leuk Lymphoma; 2018 May; 59(5):1163-1171. PubMed ID: 28901817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
    Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
    Michallet AS; Lebras LL; Bauwens DD; Bouafia-Sauvy FF; Berger FF; Tychyj-Pinel CC; D'Hombres AA; Salles GG; Coiffier BB
    J Hematol Oncol; 2013 Jul; 6():45. PubMed ID: 23816219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
    Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Pulsoni A; Della Starza I; Cappelli LV; Tosti ME; Annechini G; Cavalli M; De Novi LA; D'Elia GM; Grapulin L; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jan; 188(2):249-258. PubMed ID: 31385309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
    Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
    Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
    Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
    J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?
    Vargo JA; Gill BS; Balasubramani GK; Beriwal S
    Cancer; 2015 Sep; 121(18):3325-34. PubMed ID: 26042364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualized management of follicular lymphoma.
    Bai B; Huang HQ
    Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
    Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M
    Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of follicular lymphoma.
    Izutsu K
    J Clin Exp Hematop; 2014; 54(1):31-7. PubMed ID: 24942944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.